“A combination treatment composed of the PARP inhibitor olaparib and the investigational PI3K inhibitor BKM120 demonstrated activity and safety for women with triple-negative breast cancer or high-grade serous ovarian cancer, according to study findings presented at the American Association for Cancer Research Annual Meeting.
“High-grade serous ovarian cancer and triple-negative breast cancer are similar in that they often have germline BRCA mutations, have a sensitivity to platinum agents and have high copy number alterations based on The Cancer Genome Atlas, according to study background. Further, preclinical data have suggested olaparib (Lynparza, AstraZeneca) is synergistic with BKM120 (Novartis) and BYL719 (Novartis) in both cancers.
“Ursula A. Matulonis, MD, medical director of gynecologic oncology at the Susan F. Smith Center for Women’s Cancers at Dana-Farber Cancer Institute and associate professor of medicine at Harvard University Medical School, and colleagues evaluated olaparib plus BKM120 in 12 patients with triple-negative breast cancer and 34 patients with high-grade serous ovarian cancer. Thirty-five patients had germline BRCA mutations.
“ ‘This is one area where we in ovarian cancer are in the forefront,’ Matulonis said during a press conference. ‘We are using an FDA-approved biomarker through germline BRCA status to basically say when a patient is eligible to receive olaparib.’ “
Editor’s note: After initial treatment, some cancer patients receive maintenance therapy to keep their cancer from returning. In a recent clinical trial with volunteer patients, scientists tested the effectiveness of maintenance therapy for platinum-sensitive recurrent serous ovarian cancer. Some of the women had BRCA1 or BRCA2 mutations, and some did not. Also, all of the women had previously been treated with platinum-based chemotherapy, and experienced tumor shrinkage or complete disappearance of their tumors. In the clinical trial, scientists randomly divided the women into two groups. One group received maintenance therapy with the drug olaparib, and for comparison, the other group was treated with a “fake” placebo drug. The scientists found that women with BRCA1 or BRCA2 mutations were more likely to benefit from the maintenance therapy treatment than women without BRCA mutations.
“Women with platinum-sensitive recurrent serous ovarian cancer who harbored BRCA mutations are more likely than BRCA wild-type patients to benefit from maintenance monotherapy with olaparib, results of a phase 2 study suggest.
“ ‘To our knowledge, our study is the first phase 2 trial in ovarian cancer to show that patients with BRCA1 or BRCA2 mutations respond preferentially to a PARP inhibitor,’ Jonathan Ledermann, MD, of UCL Cancer Institute at University College London, and colleagues wrote.
“Ledermann and colleagues conducted a randomized, double blind study that included 265 women with platinum-sensitive recurrent serous ovarian cancer. All patients received at least two platinum-based regimens and demonstrated a complete or partial response to their most recent platinum-based regimen.”